CDXS - コデクシス （Codexis Inc.）

Currently, Codexis Inc.’s (CDXS) stock is trading at $10.88, marking a gain of 4.02% from last night’s close. At this price, the stock is -74.10% below its 52-week high of $42.01 and 34.16% above its 52-week low of $8.11. Based on the past 30-day period, the stock price is -6.04% below the high and +34.16% … Is Codexis Inc. (NASDAQ:CDXS) stock a better investment at this time? Read More »

Codexis, Inc. has been given an average rating of “Buy” by the six research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the…

Codexis <> along with Merck (MRK) announced the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates.The data were…

In last trading session, Codexis Inc. (NASDAQ:CDXS) saw 0.55 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $9.16 trading at -$0.45 or -4.68% at ring of the bell on the day assigns it a market valuation of $623.61M. That closing price of CDXS’s stock is at … Codexis Inc. (NASDAQ:CDXS): Buy, Sell Or Hold At $9.16? Read More »

During the last session, Codexis Inc. (NASDAQ:CDXS)’s traded shares were 0.81 million, with the beta value of the company hitting 1.99. At the end of the trading day, the stock’s price was $10.14, reflecting an intraday loss of -4.07% or -$0.43. The 52-week high for the CDXS share is $42.01, that puts it down -314.3 … Boom Or Bust: Where Does Codexis Inc. (NASDAQ: CDXS) Stock Go From Here? Read More »

REDWOOD CITY, Calif. and KALAMAZOO, Mich., July 26, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection and hop extracts for the food and beverage industry, announced that the companies have expanded their research collaboration and entered into an exclusive supply agreement for a novel enzyme to produce Kalsecs newest natural hop acid.

REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver ® platform technology transfer with Novartis Pharma AG (Novartis) today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver ® to develop novel performance enzymes for use in the manufacture of pharmaceutical products.

REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter.

Codexis, Inc. (NASDAQ:CDXS)s traded shares stood at 636,886 during the last session, with the companys beta value hitting 1.27. At the close of trading, the stocks price was $22.54, to imply an increase of 0.94% or $0.21 in intraday trading. The CDXS shares 52-week high remains $29.56, putting it -31.14% down since that peak but []

Every night, Cathie Wood’s Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause certain stocks to see a spike in the after-hours session. Here’s a list of what the hedge fund bought or sold on Tuesday. 3D Systems Corp (NYSE: DDD ): Bought 558,900 shares of the printing engineering company, representing about 0.46% of the ETF. 3D shares closed 9.62% lower at $26.22 on Tuesday and rose 1.07% in the after-hours. It has a 52-week high of $56.5 and low of $4.60. Accolade Inc (NASDAQ: ACCD ): Bought 38,112 shares of the personalized health-tech company, representing about 0.016% of the company. Accolade shares closed 2.2% lower at $42.03 on Tuesday and were further down 1.26% in the after-hours. It has a 52-week high of $62.25 and low of $28.68. Codexis Inc (NASDAQ: CDXS ): Bought 138,712 shares in the protein engineering company, representing just about 0.032% of the ETF. Codexis shares closed 2.44% lower at $21.95 on Tuesday.

DUBLIN--(BUSINESS WIRE)--The "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area; By Form, By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global proteinase K market size is predicted to reach US$ 107.5 Million by 2027 The report "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Infectious diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, N

Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Phenylketonuria Treatment market with detailed

Codexis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to the virus crisis. The recent improvement in fiscal […] The post Codexis (CDXS) may be moving closer to profitability, after beating slowdown first appeared on AlphaStreet .